Skip to Content
Merck
CN
  • Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection.

Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection.

Cell host & microbe (2022-11-19)
Philip J M Brouwer, Aleksandar Antanasijevic, Adam J Ronk, Helena Müller-Kräuter, Yasunori Watanabe, Mathieu Claireaux, Hailee R Perrett, Tom P L Bijl, Marloes Grobben, Jeffrey C Umotoy, Angela I Schriek, Judith A Burger, Khadija Tejjani, Nicole M Lloyd, Thijs H Steijaert, Marlies M van Haaren, Kwinten Sliepen, Steven W de Taeye, Marit J van Gils, Max Crispin, Thomas Strecker, Alexander Bukreyev, Andrew B Ward, Rogier W Sanders
ABSTRACT

The Lassa virus is endemic in parts of West Africa, and it causes hemorrhagic fever with high mortality. The development of a recombinant protein vaccine has been hampered by the instability of soluble Lassa virus glycoprotein complex (GPC) trimers, which disassemble into monomeric subunits after expression. Here, we use two-component protein nanoparticles consisting of trimeric and pentameric subunits to stabilize GPC in a trimeric conformation. These GPC nanoparticles present twenty prefusion GPC trimers on the surface of an icosahedral particle. Cryo-EM studies of GPC nanoparticles demonstrated a well-ordered structure and yielded a high-resolution structure of an unliganded GPC. These nanoparticles induced potent humoral immune responses in rabbits and protective immunity against the lethal Lassa virus challenge in guinea pigs. Additionally, we isolated a neutralizing antibody that mapped to the putative receptor-binding site, revealing a previously undefined site of vulnerability. Collectively, these findings offer potential approaches to vaccine and therapeutic design for the Lassa virus.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Alpha-lytic protease
Sigma-Aldrich
3, 3′,5 ,5′-Tetramethylbenzidine Liquid Substrate, Supersensitive, for ELISA, ready to use solution